drugset / Trial / NCT05237388
Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney Disease
Phase 2
Completed
8 enrolled
Duke University
Eli Lilly and Company · collabNational Institute on Minority Health and Health Disparities (NIMHD) · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine if the drug, baricitinib, is safe and effective in reducing high levels of albumin in the urine (albuminuria) in African American/Blacks with APOL1- associated focal segmental glomerulosclerosis (FSGS) and non-diabetic APOL1-associated chronic kidney disease due to hypertension (HTN-CKD).
Timeline
- Start
- 2023-04-20
- Primary completion
- 2026-04-03
- Completion
- 2026-04-03
Publications
- Barrett N, Odera JO, Bethea K, Smith M, Sadeghpour A, Matthews L, Lucas A, Godbee RL, Dowdy O, Miles L, Olabisi OA; CARE Community Partners. Hybrid Community-Electronic Health Record Approaches to Apolipoprotein L1 Kidney Disease Screening and Clinical Trials among Black Individuals. J Am Soc Nephrol. 2026 Mar 3. doi: 10.1681/ASN.0000001062. Online ahead of print.
- Shen CL, Richardson A, Martin-Fernandez M, Malle L, Buta S, Patel A, Rosberger H, Lim J, Horesh M, Saland J, Bogunovic D. Cytokine-Driven Janus Kinase Signal Transducer and Activator of Transcription Pathway Hyperactivity Predicts Disease Severity in Pediatric FSGS. Kidney360. 2026 Feb 1;7(2):260-268. doi: 10.34067/KID.0000001010. Epub 2025 Nov 14.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | — | — |